



Earthwatch: Generic Meds

How cheap drugs are faring amid global challenges

June 1, 2005 By Josh Sparber

In January, the **U.S.** approved its first primary-treatment generic AIDS med for the President's \$15 billion global AIDS initiative, PEPFAR.

Two **Guatemalan** demonstrators died March 15 when nationwide protests over the ratification of a trade treaty that will restrict generic meds, including HIV meds, turned violent.

On March 16, **Brazil** threatened to break U.S. drug patents unless American drug companies shared drugmaking technology with local pharma factories.

In **Kenya**, where 77 percent of medicated HIVers take generics, hundreds of protesters rallied unsuccessfully March 18 against Indian anti-generic legislation at Nairobi's Indian High Commission.

Belgian generics company Propharex is sending a turnkey generics factory piecemeal to the African nation of Gabon, aiming to boost production of affordable HIV meds.

On March 23, **India** tightened its anti-generics legislation, possibly restricting generic production of future AIDS meds but ensuring continued membership in the World Trade Organization.

© 2026 Smart + Strong All Rights Reserved.

<http://beta.docker.poz.com/article/Earthwatch-Generic-Meds-122-6799>